Cargando…

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer

BACKGROUND: The early identification of treatment effect is wanted in several settings, including the management of metastatic colorectal cancer (mCRC). A potential universal marker is circulating tumor DNA (ctDNA). Our prospective study explored the association between progression-free survival (PF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomsen, Caroline B., Hansen, Torben F., Andersen, Rikke F., Lindebjerg, Jan, Jensen, Lars H., Jakobsen, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252368/ https://www.ncbi.nlm.nih.gov/pubmed/32518596 http://dx.doi.org/10.1177/1758835920918472

Ejemplares similares

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
por: Jensen, Lars Henrik, et al.
Publicado: (2019)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
por: Thomsen, C. B., et al.
Publicado: (2018)

The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer
por: Hansen, Torben F., et al.
Publicado: (2010)

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
por: Hansen, Torben Frøstrup, et al.
Publicado: (2012)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer
por: Thomsen, Caroline Emilie B., et al.
Publicado: (2017)

The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
por: Wen, Sara Witting Christensen, et al.
Publicado: (2021)

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
por: Wen, Sara W. C., et al.
Publicado: (2020)

Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
por: Wen, Sara W. C., et al.
Publicado: (2021)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
por: Blomberg, Kristian, et al.
Publicado: (2021)

Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
por: Brenner Thomsen, Caroline, et al.
Publicado: (2022)

Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer
por: Faaborg, Louise, et al.
Publicado: (2022)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
por: Borg, Morten, et al.
Publicado: (2023)

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Wen, Sara Witting Christensen, et al.
Publicado: (2023)

Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts
por: Hansen, Torben Frøstrup, et al.
Publicado: (2018)

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
por: Callesen, Louise Bach, et al.
Publicado: (2023)

Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
por: Jensen, Lars Henrik, et al.
Publicado: (2023)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
por: Hansen, T F, et al.
Publicado: (2015)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Spindler, K-L G, et al.
Publicado: (2014)

Local staging of sigmoid colon cancer using MRI
por: Dam, Claus, et al.
Publicado: (2017)

The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort
por: Hansen, Torben Frøstrup, et al.
Publicado: (2014)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations
por: Olsen, Dorte Aa., et al.
Publicado: (2020)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review
por: Wen, Sara Witting Christensen, et al.
Publicado: (2022)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2017)

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023)

Approaches for Health Effect Characterization in Risk-Benefit Assessment of Foods: A Comparative Case Study
por: Thomsen, Sofie Theresa, et al.
Publicado: (2021)

The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
por: Andersen, Line Bechsgaard, et al.
Publicado: (2022)

Colorectal cancer mortality 10 years after a single round of guaiac faecal occult blood test (gFOBT) screening: experiences from a Danish screening cohort
por: Bjerrum, Andreas, et al.
Publicado: (2016)

Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer
por: Xu, Fei, et al.
Publicado: (2021)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2016)

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
por: Yuan, Zhen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qbbig5tscgh5biaa9rcofrc6g2